Alterity Therapeutics Ltd
ATHE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001131343
In the last 90 days, Alterity Therapeutics Ltd insiders filed 1 open-market purchase and 0 sales; 21 institutions reported holding it in 13F filings for Q2 2026, worth $2.12M in total; no superinvestor holds it.
Other share classesPRNAF
Q4 2024 vs. Q3 2024
How the institutions holding Alterity Therapeutics Ltd changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 13 | 13 | 0 |
| Shares | 112.7K | 124.3K | +11.6K (+10.3%) |
| Value | $148.6K | $415.9K | +$267.3K (+179.9%) |
New holders (3)
Institutions that held Alterity Therapeutics Ltd at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Point72 Asset Management, L.P. | 32,627 | $108.0K | 0.00% |
| BNP Paribas Arbitrage, SA | 8,790 | $29.1K | 0.00% |
| Northwestern Mutual Wealth Management Co | 16 | $53 | 0.00% |
Sold out (3)
Institutions that held Alterity Therapeutics Ltd at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Susquehanna International Group, LLP | 13,932 | $18.7K |
| Citadel Advisors LLC | 11,488 | $15.4K |
| Providence Capital Advisors, LLC | 200 | $263 |